AstraZeneca (LON:AZN – Get Rating)’s stock had its “buy” rating reissued by equities researchers at Shore Capital in a research note issued to investors on Monday, Marketbeat.com reports.
A number of other equities analysts have also issued reports on the stock. UBS Group set a £101 ($122.04) price target on shares of AstraZeneca in a research report on Tuesday, June 14th. Credit Suisse Group set a £110 ($132.91) target price on shares of AstraZeneca in a research report on Monday, August 1st. Berenberg Bank reaffirmed a “buy” rating and issued a £115 ($138.96) price target on shares of AstraZeneca in a report on Tuesday, July 26th. Jefferies Financial Group set a GBX 9,800 ($118.41) price objective on AstraZeneca in a research note on Thursday, July 7th. Finally, Deutsche Bank Aktiengesellschaft restated a “buy” rating and issued a £120 ($145.00) target price on shares of AstraZeneca in a research note on Wednesday, August 31st. Eight equities research analysts have rated the stock with a buy rating, Based on data from MarketBeat, AstraZeneca presently has a consensus rating of “Buy” and an average price target of £106.96 ($129.24).
AstraZeneca Stock Performance
Shares of LON:AZN traded down GBX 72.25 ($0.87) during trading on Monday, hitting £105.46 ($127.43). The stock had a trading volume of 1,403,451 shares, compared to its average volume of 2,139,321. The company has a quick ratio of 0.67, a current ratio of 0.96 and a debt-to-equity ratio of 87.31. AstraZeneca has a 12-month low of GBX 8,029 ($97.02) and a 12-month high of £115.40 ($139.44). The stock has a market capitalization of £163.41 billion and a price-to-earnings ratio of -179.35. The stock has a 50-day simple moving average of £109.35 and a two-hundred day simple moving average of £102.92.
About AstraZeneca
AstraZeneca PLC, a biopharmaceutical company, focuses on the discovery, development, manufacturing, and commercialization of prescription medicines. Its marketed products include Calquence, Enhertu, Faslodex, Imfinzi, Iressa, Koselugo, Lumoxiti, Lynparza, Orpathys, Tagrisso, and Zoladex for oncology; Brilinta/Brilique, Bydureon/Byetta, BCise, Byetta, Crestor, Evrenzo, Farxiga/Forxiga, Komboglyze/Kombiglyze XR, Lokelma, Onglyza, Qtern, and Xigduo/Xigduo XR for cardiovascular, renal, and metabolism diseases; Bevespi Aerosphere, Breztri Aerosphere, Daliresp/Daxas, Duaklir Genuair, Fasenra, Pulmicort, Saphnelo, Symbicort, and Tudorza/Eklira/Bretaris for respiratory and immunology; and Andexxa/Ondexxya, Kanuma, Soliris, Strensiq, and Ultomiris for rare diseases.